Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis

scientific article published on December 2006

Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/ART.22255
P698PubMed publication ID17136752
P5875ResearchGate publication ID6661568

P50authorJerry AvornQ6183214
Sebastian SchneeweissQ60162120
Michael E WeinblattQ88922582
Jeffrey N KatzQ89419301
Daniel H SolomonQ91503755
P2093author name stringRaisa Levin
Soko Setoguchi
P2860cites workPrediction of Coronary Heart Disease Using Risk Factor CategoriesQ22241923
Taking glucocorticoids by prescription is associated with subsequent cardiovascular diseaseQ45151895
The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results.Q52373114
P433issue12
P921main subjectcirculatory systemQ11068
rheumatoid arthritisQ187255
hospitalizationQ3140971
P304page(s)3790-3798
P577publication date2006-12-01
P1433published inArthritis & RheumatologyQ4797636
P1476titleImmunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis
P478volume54

Reverse relations

cites work (P2860)
Q425338856-Mercaptopurine, monocytes, and atherosclerosis
Q36434758A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1
Q36434813A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2.
Q34154483Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission
Q64123686An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches
Q55008598Analysis of Drug Effects on Primary Human Coronary Artery Endothelial Cells Activated by Serum Amyloid A.
Q37169541Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis.
Q43578147Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study
Q36253671Atherosclerosis and rheumatoid arthritis: more than a simple association
Q38365624Atherosclerotic vascular disease in the autoimmune rheumatologic patient
Q56243555Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
Q85069915Biologics and cardiovascular risk
Q90666678Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate
Q33713206Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature
Q33943374Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment
Q36757060Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study
Q37859676Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity
Q34081242Cardiovascular involvement in autoimmune diseases
Q37808570Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Q38260198Cardiovascular risk and the use of biologic agents in rheumatoid arthritis
Q26738461Cardiovascular risk assessment in rheumatoid arthritis - controversies and the new approach
Q36361147Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs
Q37142052Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs
Q37026106Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Q37300823Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis
Q39829013Comorbid conditions are associated with healthcare utilization, medical charges and mortality of patients with rheumatoid arthritis
Q40961450Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis
Q80093117Does treatment with DMARDs decrease the risk of cardiovascular disease in patients with RA?
Q36241707Effects of Methotrexate on Carotid Intima-media Thickness in Patients with Rheumatoid Arthritis.
Q37883018Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.
Q99638169Ethnic Disparities in Atherosclerotic Cardiovascular Disease Incidence and Prevalence Among Rheumatoid Arthritis Patients in the United States: a Systematic Review
Q34238357Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity
Q28540791Harmful effects of the azathioprine metabolite 6-mercaptopurine in vascular cells: induction of mineralization
Q40212689High prevalence of cardiovascular comorbidities in patients with rheumatoid arthritis from a population-based cross-sectional study of a Japanese health insurance database.
Q37245192Infliximab improves vascular stiffness in patients with rheumatoid arthritis
Q34081364Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study
Q34019267Initiation of rheumatoid arthritis treatments and the risk of serious infections
Q36191250Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases
Q37398563Interpreting studies of cardiovascular mortality in rheumatoid arthritis: the importance of timing
Q37704498Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial.
Q37975943Managing cardiovascular risk in patients with chronic inflammatory diseases.
Q26998660Modulation of 11β-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammation
Q46546902Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques.
Q35243557No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease
Q38098935Novel risk factors for cardiovascular disease in rheumatoid arthritis
Q34773536Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions
Q36951050Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors
Q44051899Prevalence and predictive factors of comorbidity in rheumatoid arthritis patients monitored prospectively from disease onset up to 20 years: lack of association between inflammation and cardiovascular disease
Q28709376Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis
Q31005025Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data
Q40386790Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.
Q37632485Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review
Q40850003Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis
Q38794852Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity?
Q99581776Rheumatoid Arthritis is Not Associated with Increased Inpatient Mortality in Patients Admitted for Acute Coronary Syndrome
Q82076745Rheumatoid arthritis and cardiovascular disease
Q37310447Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings
Q33648507Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis
Q33714074Risk of stroke in patients with rheumatism: a nationwide longitudinal population-based study.
Q41176187Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides
Q59352564Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314
Q38797087Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort.
Q36968832Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus
Q35377706Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease
Q37894193TNF alpha antagonist therapy and safety monitoring
Q92885360Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection
Q33892790The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study
Q50233845Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Q37230796Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease
Q44293608Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis
Q37808889Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review
Q42575985Use of administrative claims data for comparative effectiveness research of rheumatoid arthritis treatments
Q35754240Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach.
Q35135179Validity of myocardial infarction diagnoses in administrative databases: a systematic review
Q35954625What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.
Q84815164[Cardiovascular comorbidity and its risk factors in rheumatoid arthritis]

Search more.